Alcohol Consumption Has a Protective Effect against Hematological Malignancies: a Population-Based Study in Sweden Including 420,489 Individuals with Alcohol Use Disorders  by Ji, Jianguang et al.
www.neoplasia.com
Volume 16 Number 3 March 2014 pp. 229–234.e1 229
Address al
University
1 J.J., K.S.,
analysis, an
2This wor
Working L
had no rol
researchers
3Ethical ap
4Suppleme
5This artic
Received 2
Copyright
http://dx.dAlcohol Consumption Has a
Protective Effect against
Hematological Malignancies: a
Population-Based Study in Sweden
Including 420,489 Individuals with
Alcohol Use Disorders1,2,3,4,5l correspondence to: Jianguang Ji, Center for Primary Health Care Research,
Hospital, 205 02 Malmö, Sweden. E-mail: Jianguang.ji@med.lu.se
and J.S. were responsible for the study concept and design. J.S. and K.S. obtaine
d drafted the manuscript. All authors revised it for important intellectual con
k was supported by grants to K.S. from the Swedish Research Council (K2009-
ife and Social Research (2007–1754) as well as Avtal om Läkarutbildning och Fo
e in the design and conduct of the study, in the collection, analysis, and interp
were independent of the funding agencies. Conflict of interests: None.
proval: This study was approved by the Regional Ethical Review Board of Lu
ntary information is available at Leukemia's website.
le refers to supplementary material, which is designated by Table W1 and is a
9 November 2013; Revised 14 February 2014; Accepted 17 February 2014
© 2014 Neoplasia Press, Inc. All rights reserved 1476-5586/14/$25.00
oi.org/10.1016/j.neo.2014.03.003Jianguang Ji*, Jan Sundquist*,†
and Kristina Sundquist*,†
*Center for Primary Health Care Research, Lund University/
Region Skåne, Malmö, Sweden; †Stanford Prevention
Research Center, Stanford University School of Medicine,
Stanford, CA, USAAbstract
BACKGROUND: It has been suggested that alcohol consumption is associated with increased risk of a few solid
cancers, although studies that examined the association with hematological malignancies have shown
inconsistent results. In this study, we examined the risk of hematological malignancies among individuals who
had alcohol use disorders (AUDs) in Sweden. METHODS: Individuals with AUDs were identified from the
nationwide Swedish Hospital Discharge Register and Outpatient Register, the Crime Register, and the
Prescription Drug Register, and they were linked to the Swedish Cancer Registry to calculate standardized
incidence ratios (SIRs) of hematological malignancies, using those Swedes without AUDs as a reference. In
addition, we used a quasi-experimental sibling design to investigate the odds ratios among sibling pairs who
were discordant with AUDs. RESULTS: A total of 420,489 individuals were identified with AUDs. After more than
15 million person-years of follow-up, a total of 1755 individuals developed hematological malignancies
demonstrating a low risk, i.e., SIR = 0.60 (95% confidence interval = 0.57-0.63). People with AUDs had low risks
for developing specific types of malignancies. The lowest risk (0.51) was for leukemia, followed by myeloma
(0.52), non-Hodgkin lymphoma (0.65), and Hodgkin disease (0.71). The risk was lower among AUDs identified at
an older age. The low risks of hematological malignancies were also noted using sibling analysis.
CONCLUSIONS: Our data suggest that alcohol consumption has a protective effect against hematological
malignancies. However, further studies are needed to identity the underlying mechanisms of the protective
effect of alcohol consumption against hematological malignancies.
Neoplasia (2014) 16, 229–234.e1Clinical Research Center, Floor 11, Building 28, Jan Waldenströms gata 35, Skåne
d funding and acquired the data. J.J. analyzed and interpreted the data, did the statistical
tent. J.S. is the guarantor.
70X-15428-05-3 and K2012-70X-15428-08-3), to J.S. from the Swedish Council for
rskning funding from Region Skåne awarded to J.S., K.S., and J.J. The funding agencies
retation of the data, or in the preparation, review, or approval of the manuscript. The
nd University in Sweden.
vailable online at www.neoplasia.com.
230 Alcohol and Hematological Malignancies Ji et al. Neoplasia Vol. 16, No. 3, 2014Introduction
Alcohol use disorders (AUDs), including alcohol abuse and/or
dependence, is a substantial worldwide health problem and a major
contributor to the global burden of diseases [1,2]. In Sweden, AUDs
affect around 18% of men and 5% of women [3,4]. Many diseases,
including depressive episodes, severe anxiety, insomnia, suicide, abuse
of other drugs, hypertension, heart disease, stroke, liver cirrhosis, fatal
accident, and some types of solid cancers, are potentially related to
excessive alcohol use [1,2]. According to the report from the
International Agency for Research on Cancer [5,6], a few cancer sites,
including the oral cavity, pharynx, larynx, esophagus, liver, color-
ectum, and female breast, are believed to be causally related to alcohol
consumption. Acetaldehyde derived from the metabolism of ethanol
in alcohol contributes to the development of malignant esophageal
cancers [5,6], but the mechanism of carcinogenesis to the other
cancers is not clear.
Hematological malignancies include a heterogeneous group of
malignancies, and their etiology is not fully understood. Studies that
examine the associations of alcoholic beverage consumption with the
risk for these hematological malignancies are limited compared to
studies on the associations with solid cancers [7]. Interestingly, several
previous studies found a negative association of alcohol consumption
with non-Hodgkin lymphoma [8–12]. However, inconsistent data are
reported in many other studies [13–15]. Possible reasons for the
observed inconsistencies are different study designs, small numbers of
cases, and bias due to reporting of alcohol consumption. Studies
examining the associations with Hodgkin lymphoma, myeloma, and
leukemia are also limited [7]. In this study, we used the national Swedish
Registries including data from a total population to examine the risk of
hematological malignancies (Hodgkin and non-Hodgkin lymphomas,
myeloma, and leukemia) among a total of 420,489 individuals with
AUDs, compared to those without AUDs. In addition, we used the
quasi-experimental sibling design, which was believed to provide
stronger causal evidence by controlling for unmeasured confounding
factors (unmeasured genetic and environmental factors) [16], to
confirm our observation by studying the effect of different AUD
exposures among siblings on hematological malignancies.
Methods
This study was approved by the Ethics Committee at Lund University
(Malmö, Sweden), 2013. Patients diagnosed with AUDs were
identified using data from the following: 1) the Swedish Hospital
Discharge Register and Outpatient Register for 1987 to 2010
(international classification of diseases-9: 291A-291F, 291W, 291X,
303, and 305A; and ICD-10: F10), 2) the Crime Register for 1973 to
2010 (to identify individuals who committed alcohol-related crimes),
and 3) the Prescription Drug Register for 2005 to 2010 (to identify
individuals prescribed with disulfiram, naltrexone, or acamprosate,
which are usually used to treat AUDs) [17].
The Swedish Hospital Discharge Register contains hospital
discharge records for all Swedish residents. Data were initially
collected in the 1960s by 26 regional health authorities and were
compiled by the National Board of Health and Welfare. From 1987
forward, the register included nationwide data. The National Board
of Health and Welfare estimates that it contains information on 99%
of all public hospitalizations. Because Sweden has very few providers
of private inpatient care, this registry covers the majority of hospital
admissions. Each year, 1.5 million records are added to the Hospital
Discharge Register. The results of a recent external review suggest thatthe overall accuracy of diagnoses in this register is about 85% to 95%
[18]. The information for each hospitalization comprises dates of
admission and discharge, hospital and clinic codes, and up to eight
discharge diagnosis codes, the first of which defines the principal
cause of hospitalization. Patients were identified as AUDs if any of the
eight discharge codes contained the ICD codes listed above. The
Swedish Outpatient Register was created in 2001 by the National
Board of Health and Welfare. Although data on outpatient care from
public hospitals are almost 100% complete, the register contains no
data from small private outpatient clinics, meaning that its overall
national coverage is around 80%.
The Swedish Crime Register contains complete nationwide data on
all convictions, including those for alcohol abuse, from 1973 to 2010.
Individuals with alcohol-associated drunk driving were identified as
AUDs. The Swedish Prescribed Drug Register has 100% coverage.
Information on prescriptions and expenditures for prescribed drugs in
the entire Swedish population covers the period July 2005 to
December 2010. From the above-listed Swedish Registers, we
identified 420,489 unique individuals with a phenotype of AUDs
between 1973 and 2010 (lifetime prevalence in Sweden ~3.8%). We
did a sensitivity analysis to examine the risks of cancers in the
esophagus and upper aerodigestive tract (including oral, larynx, and
pharynx), which are known to be associated with alcohol
consumption, among individuals with AUDs to see whether AUDs
identified in this study can represent the general population with
excess alcohol consumption (Table W1).
We further linked these individuals with AUDs to the Swedish
Cancer Registry to identify all incident cases of hematological
malignancies during the study period. Hematological malignancies
examined in this study include non-Hodgkin lymphoma (interna-
tional classification of diseases-7 codes 200, 202, and 2041),
Hodgkin disease (201), myeloma (203), and leukemia (204-209,
except 2041). We also examined the risks of a few subtype
lymphomas. Only those subtypes that were significantly associated
with AUDs were presented (diffuse, follicular non-Hodgkin
lymphoma and mixed cellularity and nodular sclerosis classic
Hodgkin lymphoma). The Swedish Cancer Registry was founded
in 1958 by the National Board of Health and Welfare. Since the mid-
80s, there are six regional registries associated with the oncological
centers in each medical region of Sweden where the registration,
coding, major check-up, and correction work are performed with a
close to 100% coverage in the whole Sweden. In Sweden, it is
compulsory for clinicians and pathologists/cytologists to report all
newly diagnosed cancers to the Cancer Registry [19]. Additional
linkages were made to the Swedish National Population and Housing
Census [20] to obtain information on individual-level characteristics,
such as year of birth, sex, place of living, and country of birth, to the
Cause of Death Register to identify date of death, and to the
Emigration Registry to identify date of emigration. All linkages were
performed using individual national identification numbers, which
were replaced with serial numbers to preserve anonymity.
Among individuals with AUDs including a total of 420,489, we
calculated person-years at risk for the hematological malignancies
from the latter from the date of birth, immigration, or 1 January 1961
(when the Death of Cause Registry was started in Sweden) to the
earliest of the date of diagnosis of cancer, death, emigration, or the
end of the study period (31 December 2010). Standardized incidence
ratios (SIRs) were calculated as the ratio of the observed to expected
number of cases [21,22]. The expected number of cases was
Table 1. Basic Characteristics among Individuals with AUDs in Sweden (1973-2010).
Male Female All
No. % No. % No. %
Age at identification
b20 30,390 9.4 16,979 17.4 47,369 11.3
20-29 65,495 20.3 15,258 15.7 80,753 19.2
30-39 56,729 17.6 14,989 15.4 71,718 17.1
40-49 65,333 20.2 20,270 20.8 85,603 20.4
50-59 54,412 16.8 15,816 16.2 70,228 16.7
60+ 50,776 15.7 14,042 14.4 64,818 15.4
Period
b1990 38,201 11.8 10,239 10.5 48,440 11.5
1990-1994 90,592 28.0 16,305 16.7 106,897 25.4
1995-1989 57,215 17.7 15,059 15.5 72,274 17.2
2000-2004 66,602 20.6 23,359 24.0 89,961 21.4
2005+ 70,525 21.8 32,392 33.3 102,917 24.5
Education (years)
≤9 121,273 37.5 32,775 33.7 154,048 36.6
10-11 101,464 31.4 29,328 30.1 130,792 31.1
12+ 96,385 29.8 34,252 35.2 130,637 31.1
Unknown 4,013 1.2 999 1.0 5,012 1.2
Region
Big cities 152,679 47.2 48,105 49.4 200,784 47.8
South 106,096 32.8 29,756 30.6 135,852 32.3
North 50,469 15.6 14,453 14.8 64,922 15.4
Unknown 13,891 4.3 5,040 5.2 18,931 4.5
All 323,135 100.0 97,354 100.0 420,489 100.0
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AUDs. SIRs were standardized by 5-year age group, sex, 5-year time
period, education level (≤9, 10-11, and 12+), and region (big cities,
south Sweden, and north Sweden) [23]. The 95% confidence
intervals (CIs) were calculated and rounded to two decimal places for
SIR, assuming a Poisson distribution [23].
We further selected a subsample of siblings with discordant AUDs
exposure to examine the odds ratios (OR) of hematological
malignancies. Only those families with at least two siblings and at
least one sibling with AUDs were selected. For those families with
more than two siblings, those siblings without AUDs but with their
birth year close to the sibling with AUDs were selected. In total, we
selected 20,084 sibling pairs with discordant AUDs. We used
conditional logistic regression to calculate OR, adjusted for year of
birth and gender. All analyses were performed using SAS version 9.1
(SAS Institute, Cary, NC).
The study was approved by the Ethics Committee at Lund
University.Table 2. Risk of Hematological Malignancies among Individuals with AUDs.
Disease Men Wom
O SIR 95% CI O
Non-Hodgkin lymphoma 791 0.64 0.60 0.69 150
Diffuse large B cell 107 0.83 0.68 1.01 24
Follicular 48 0.72 0.53 0.96 14
Hodgkin disease 184 0.70 0.60 0.81 41
Mixed cellularity classic 15 0.86 0.48 1.42 3
Nodular sclerosis classic 58 1.27 0.96 1.64 12
Myeloma 167 0.53 0.45 0.61 29
Leukemia 325 0.52 0.46 0.58 68
Acute lymphatic leukemia 55 0.49 0.37 0.63 17
Acute myeloid leukemia 54 0.31 0.24 0.41 9
Chronic myeloid leukemia 52 0.53 0.40 0.70 11
All 1467 0.60 0.57 0.63 288
O, observed number of cases; SIR, standardized incidence ratio; CI, confidence interval.
Bold type, 95% CI does not include 1.00.Results
The basic characteristics of individuals with AUDs in Sweden
identified between 1973 and 2010 are presented in Table 1. From a
total of 420,489 individuals, three times as many men versus women
were identified with AUDs. The median age at identification was 41
years for men and 40 years for women. The prevalence of AUDs was
more common among individuals with low education levels and those
living in big cities.
The risk of hematological malignancies among the individuals
with AUDs is presented in Table 2, which was standardized by age,
sex, time period, education level, and region. After more than 15
million person-years of follow-up, a total of 1755 individuals were
diagnosed with hematological malignancies. The overall risk was
40% lower than in the general population without AUDs (SIR =
0.60, 95% CI = 0.57-0.63). For specific types of malignancies,
most of them exhibited SIRs lower than 1.0 with the exception of
nodular sclerosis classic Hodgkin lymphoma in men and mixed
cellularity classic for women. The low risk of hematological
malignancies was consistent in both men and women, although the
number of cases identified with hematological malignancies was
lower in women (n = 288) than in men (n = 1467).We further
calculated the risk of hematological malignancies by age at
identification of AUDs (Table 3). The risks of various types of
hematological malignancies were generally low irrespective of the
age at identification from the three registries; however, the risks
were somewhat lower among those AUDs identified at an older age
compared to those identified at a younger age.
In Table 4, we present the risks of hematological malignancies
among the siblings with AUDs compared to their siblings without
AUDs with adjustment of age. The overall risk was 0.72 (95% CI =
0.65-0.819), and all the subtypes of hematological malignancies
showed a decreased risk of OR.
In Table W1, we present our sensitivity analyses for the risk of
esophageal and upper aerodigestive tract cancers among individuals
with AUDs, and the risk was 2.41 (95% CI = 2.31-2.51) and 2.26
(95% CI = 2.10-2.43), respectively.
Discussion
In this population-based cohort study, a total of 420,489 individuals
were identified with AUDs in Sweden. This is, to our best knowledge,
the largest study examining the association of AUDs with hematological
malignancies. The primary finding in this study was that the risks ofen All
SIR 95% CI O SIR 95% CI
0.69 0.58 0.81 941 0.65 0.61 0.69
0.98 0.62 1.45 131 0.86 0.72 1.02
0.72 0.39 1.21 62 0.72 0.55 0.93
0.77 0.55 1.04 225 0.71 0.62 0.81
1.18 0.22 3.49 18 0.90 0.53 1.43
0.76 0.39 1.33 70 1.14 0.89 1.44
0.49 0.33 0.70 196 0.52 0.45 0.60
0.46 0.36 0.59 393 0.51 0.46 0.56
0.57 0.33 0.91 72 0.50 0.39 0.63
0.21 0.09 0.39 63 0.29 0.22 0.37
0.58 0.29 1.04 63 0.54 0.41 0.69
0.60 0.54 0.68 1755 0.60 0.57 0.63
Table 3. Risk of Hematological Malignancies among Individuals with AUDs by Age at Identification.
Disease b40 40-60 60+
O SIR 95% CI O SIR 95% CI O SIR 95% CI
Non-Hodgkin lymphoma 150 0.97 0.82 1.13 420 0.72 0.65 0.79 371 0.53 0.47 0.58
Diffuse large B cell 28 1.34 0.89 1.94 68 0.96 0.75 1.22 35 0.57 0.40 0.79
Follicular 9 0.93 0.42 1.77 34 0.77 0.53 1.08 19 0.59 0.36 0.93
Hodgkin disease 102 0.92 0.75 1.11 97 0.73 0.59 0.89 26 0.36 0.23 0.52
Mixed cellularity classic 9 1.05 0.48 2.00 7 0.95 0.38 1.97 2 0.49 0.05 1.82
Nodular sclerosis classic 44 1.10 0.80 1.47 19 1.20 0.72 1.88 7 1.23 0.49 2.56
Myeloma 15 0.98 0.55 1.62 104 0.77 0.63 0.94 77 0.34 0.27 0.43
Leukemia 120 0.61 0.50 0.72 160 0.55 0.47 0.65 113 0.40 0.33 0.48
Acute lymphatic leukemia 59 0.62 0.47 0.80 12 0.37 0.19 0.64 1 0.06 0.00 0.37
Acute myeloid leukemia 20 0.57 0.35 0.88 25 0.29 0.19 0.43 18 0.19 0.11 0.30
Chronic myeloid leukemia 19 0.80 0.48 1.25 26 0.49 0.32 0.72 18 0.45 0.26 0.71
All 387 0.81 0.73 0.89 781 0.68 0.64 0.73 587 0.46 0.42 0.49
O, observed number of cases; SIR, standardized incidence ratio; CI, confidence interval.
Bold type, 95% CI does not include 1.00.
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Hodgkin disease, myeloma, and leukemia, were significantly decreased
among individuals with AUDs compared to the general population
without AUDs. The risk patterns were similar in bothmen and women,
and the SIR was somewhat lower among AUDs identified at an older
age. In addition, by controlling for unmeasured confounding factors
using sibling design, the risk patterns were similar to the conventional
population-based cohort study.
The low risk of non-Hodgkin lymphoma observed in this study
was consistent with a few previous studies [8–12]. The inverse
association between non-Hodgkin lymphoma and alcohol consump-
tion was noted in a few previous case-control studies [10–12], and a
pool analysis based on these case-control studies finds that the risk of
non-Hodgkin lymphoma is 0.83 among alcohol drinkers [8],
somewhat lower than our calculated risk of 0.65. We expect that
the difference is because individuals identified with AUDs in this
study may have been heavier drinkers compared to those in previous
studies. A cohort study investigated the relation of alcohol
consumption among 35,156 Iowa women to risk of non-Hodgkin
lymphoma found that higher alcohol consumption was significantly
associated with a decreased risk of non-Hodgkin lymphoma during
the 9-year follow-up period (P trend = .03) [9]. Some inconsistent
data were reported previously [13–15]. Possible reasons for the
observed inconsistencies are different study designs and small
numbers of cases. In addition, most previous case-control studies
defined alcohol consumption using mailed questionnaire with
potential reporting bias, and many of them focused on the
associations with specific alcoholic beverages, such as wine or beer.
We found an association between AUDs and two subtypes of non-
Hodgkin lymphoma, namely, diffuse lymphoma and follicular
lymphoma. This agrees with a previous study [8]. Studies examiningTable 4. ORs of Hematological Malignancies among Siblings with AUDs Compared to Siblings
without AUDs Using Sibling Design Analysis.
Disease OR 95% CI
Non-Hodgkin lymphoma 0.72 0.61 0.85
Hodgkin disease 0.46 0.31 0.69
Myeloma 0.76 0.53 1.09
Leukemia 0.57 0.46 0.71
All 0.72 0.65 0.81
OR, odds ratio; CI, confidence interval.
Bold type, 95% CI does not include 1.00.the associations with Hodgkin lymphoma, myeloma, and leukemia
are also limited [7].The decreased risk of Hodgkin lymphoma was
also in agreement with previous reports [24,25]; however, the risk for
nodular sclerosis classic and mixed cellularity Hodgkin disease was
not lower among individuals with AUDs. Previous studies examining
the associations between AUDs and myeloma and leukemia did not
find consistent risk patterns [26–29]. In contrast, we found that the
risks of myeloma and leukemia were lower than the risk of non-
Hodgkin lymphoma among individuals with AUDs.
A review article suggests that moderate alcohol consumption can
also improve cellular and humoral immune response [30], but a very
high amount of alcohol may impair the immune function [30]. On
the basis of the fact that AUD cases identified in this study represent a
population with excessive alcohol consumption, our observation of
the inverse association with hematological malignancies could not be
explained through immune mechanisms. Previous studies suggested
that antioxidants (resveratrol) in grape skins can reduce the risk of
non-Hodgkin lymphoma [31,32]. Unfortunately, we have no
information about specific alcoholic beverages among individuals
with AUDs; thus, the reverse associations observed in our study could
not be totally attributed to consumption of wine drinking. However,
it is known that consumption of wine in Sweden has increased greatly
during the later half of the 20th century although Sweden is
historically with high consumption of distilled beverages and binge
drinking [33]. In addition, it is known that a few types of viruses are
associated with hematological malignancies [34,35]. For example, the
Epstein-Barr virus is associated with lymphoma (Burkitt and
extranodal natural killer/T cell non-Hodgkin lymphoma and
Hodgkin lymphoma), hepatitis C virus is associated with non-
Hodgkin lymphoma, Kaposi sarcoma herpesvirus is associated with
primary effusion lymphoma, human immunodeficiency virus is
associated with lymphoma, and human T cell lymphotrophic virus is
associated with adult T cell leukemia and lymphoma. A review article
by Moorer suggests that alcohol can be used for surface disinfection of
various types of viruses [36,37]. However, whether alcohol
consumption can inactivate various types of viruses in vivo and/or
in vitro is still unknown. Although it is widely known that
consumption of alcohol can increase the risk of several types of
solid cancers [5,6], the mechanisms are still unclear. The protective
effect of alcohol on hematological malignancies is somewhat a novel
finding compared to their adverse effect, and the potential
mechanisms are even unclear, to our knowledge. However, further
Neoplasia Vol. 16, No. 3, 2014 Alcohol and Hematological Malignancies Ji et al. 233studies are greatly needed to duplicate our observation, and it is
important to include more information regarding other associated risk
factors (e.g., smoking, dietary habits, and amount and frequency of
alcohol consumed over time) in future studies. Our study did not
imply the applications of excessive alcohol consumption to prevent
hematological malignancies. Instead, our study promotes research to
disentangle the underlying mechanisms of the protective effect of
alcohol consumption against hematological malignancies, which may
lead to more effective prevention of these malignancies. In addition, it
may also be interesting to examine whether the protective effect varied
by the type of alcoholic beverage.
An important strength of this study is that all the data were
retrieved from Swedish Registers with high quality and almost 100%
coverage. In addition, the number of patients included is large enough
to guarantee reliable risk estimates. The prospective study design and
the completeness of the follow-up of patients are other major
strengths of this study. Moreover, we adjusted for a number of
confounding factors, such as age, sex, education, and we used the
sibling design analysis to control for unmeasured confounding factors.
In addition, our sensitivity analyses found that the risk of esophageal
and upper aerodigestive tract cancers (Table W1) were greatly
increased and consistent with previous reports, suggesting that the
AUD cases identified in this study can represent a population with
excessive alcohol consumption in general.
One limitation of this study is that AUD cases may represent
individuals with severe alcohol consumption, and the results in this
study may not be directly applicable to the general population.
Another limitation is the lack of information about some individual-
level risk factors, such as the amount of alcohol consumption, the
presence of smoking, and dietary habits; however, the effects of these
risk factors could be somewhat minimized by adjusting for
socioeconomic factors such as education level and region of residence.
To summarize, alcohol consumption has a protective effect against
hematological malignancies. In particular, individuals with AUDs had
low risks of lymphoma, myeloma, and leukemia, and this finding was
consistent in men as well as women. However, further studies are
needed to confirm our findings and to identity the underlying
mechanisms of the protective effect of alcohol consumption against
hematological malignancies.
Acknowledgments
The authors thank the CPF's Science Editor Stephen Gilliver for his
valuable comments on the text.
References
[1] Schuckit MA (2009). Alcohol-use disorders. Lancet 373(9662), 492–501.
[2] Graham K, Bernards S, and Knibbe R, et al (2011). Alcohol-related negative
consequences among drinkers around the world. Addiction 106(8),
1391–1405.
[3] Bergman H and Källmén H (2002). Alcohol use among Swedes and a
psychometric evaluation of the alcohol use disorders identification test. Alcohol
Alcohol 37(3), 245–251.
[4] Andréasson S, Danielsson AK, and Hallgren M (2013). Severity of alcohol
dependence in the Swedish adult population: association with consumption and
social factors. Alcohol 47(1), 21–25.
[5] Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, Bouvard V, Altieri A, and
Cogliano V, WHO International Agency for Research on Cancer Monograph
Working Group (2007). Carcinogenicity of alcoholic beverages. Lancet Oncol 8
(4), 292–293.[6] Boffetta P and Hashibe M (2006). Alcohol and cancer. Lancet Oncol 7(2),
149–156.
[7] IARC Working Group on the Evaluation of Carcinogenic Risks to Humans
(2010). Alcohol consumption and ethyl carbamate. IARC Monogr Eval Carcinog
Risks Hum 96, 3–1383.
[8] Morton LM, Zheng T, Holford TR, Holly EA, Chiu BC, Costantini AS,
Stagnaro E, Willett EV, Dal Maso L, and Serraino D, et al (2005). Alcohol
consumption and risk of non-Hodgkin lymphoma: a pooled analysis. Lancet
Oncol 6(7), 469–476.
[9] Chiu BC, Cerhan JR, Gapstur SM, Sellers TA, Zheng W, Lutz CT, Wallace RB,
and Potter JD (1999). Alcohol consumption and non-Hodgkin lymphoma in a
cohort of older women. Br J Cancer 80(9), 1476–1482.
[10] Lim U, Morton LM, Subar AF, Baris D, Stolzenberg-Solomon R, Leitzmann M,
Kipnis V, Mouw T, Carroll L, and Schatzkin A, et al (2007). Alcohol, smoking,
and body size in relation to incident Hodgkin's and non-Hodgkin's lymphoma
risk. Am J Epidemiol 166(6), 697–708.
[11] Briggs NC, Levine RS, Bobo LD, Haliburton WP, Brann EA, and Hennekens
CH (2002). Wine drinking and risk of non-Hodgkin's lymphoma among men in
the United States: a population-based case-control study. Am J Epidemiol 156(5),
454–462.
[12] Nelson RA, Levine AM, Marks G, and Bernstein L (1997). Alcohol, tobacco and
recreational drug use and the risk of non-Hodgkin's lymphoma. Br J Cancer 76
(11), 1532–1537.
[13] Chang ET, Smedby KE, Zhang SM, Hjalgrim H, Melbye M, Ost A, Wolk A,
Adami HO, and Glimelius B (2004). Alcohol intake and risk of non-Hodgkin
lymphoma in men and women. Cancer Causes Control 15(10), 1067–1076.
[14] Freedman DS, Tolbert PE, Coates R, Brann EA, and Kjeldsberg CR (1998).
Relation of cigarette smoking to non-Hodgkin's lymphoma among middle-aged
men. Am J Epidemiol 148(9), 833–841.
[15] De Stefani E, Fierro L, Barrios E, and Ronco A (1998). Tobacco, alcohol, diet
and risk of non-Hodgkin's lymphoma: a case-control study in Uruguay. Leuk Res
22(5), 445–452.
[16] D'Onofrio BM, Lahey BB, Turkheimer E, and Lichtenstein P (2013). Critical
need for family-based, quasi-experimental designs in integrating genetic and
social science research. Am J Public Health 103(Suppl 1), S46–S55.
[17] Soyka M and Chick J (2003). Use of acamprosate and opioid antagonists in
the treatment of alcohol dependence: a European perspective. Am J Addict 12
(Suppl 1), S69–S80.
[18] Ludvigsson JF, Andersson E, Ekbom A, Feychting M, Kim JL, Reuterwall C,
Heurgren M, and Olausson PO (2011). External review and validation of the
Swedish national inpatient register. BMC Public Health 11, 450.
[19] Ji J and Hemminki K (2007). Risk for contralateral breast cancers in a population
covered by mammography: effects of family history, age at diagnosis and
histology. Breast Cancer Res Treat 105(2), 229–236.
[20] Hemminki K, Sundquist J, and Ji J (2012). Is family history associated with
improved survival in patients with gastric cancer?J Clin Oncol 30(25),
3150–3151 author reply 3152–3153.
[21] Rothman KJ and Greenland S (1998). Modern epidemiology (ed 2).
Philadelphia, PA: Lippincott-Raven Publishers; 1998.
[22] Breslow NE and Day NE (1987). Statistical methods in cancer research.
Volume 2 - the design and analysis of cohort studies. IARC Sci Publ 82,
1–406.
[23] Esteve J, Benhamou E, and Raymond L (1994). Statistical Methods in Cancer
Research. IARC: Lyon; 1994.
[24] Besson H, Brennan P, Becker N, De Sanjosé S, Nieters A, Font R, Maynadié M,
Foretova L, Cocco PL, and Staines A, et al (2006). Tobacco smoking, alcohol
drinking and Hodgkin's lymphoma: a European multi-centre case–control study
(EPILYMPH). Br J Cancer 95(3), 378–384.
[25] Tavani A, Pregnolato A, Negri E, Franceschi S, Serraino D, Carbone A, and La
Vecchia C (1997). Diet and risk of lymphoid neoplasms and soft tissue sarcomas.
Nutr Cancer 27(3), 256–260.
[26] Gorini G, Stagnaro E, Fontana V, Miligi L, Ramazzotti V, Nanni O, Rodella
S, Tumino R, Crosignani P, and Vindigni C, et al (2007). Alcohol
consumption and risk of leukemia: A multicenter case–control study. Leuk
Res 31(3), 379–386.
[27] Rauscher GH, Shore D, and Sandler DP (2004). Alcohol intake and incidence of
de novo adult acute leukemia. Leuk Res 28(12), 1263–1265.
[28] Pogoda JM, Nichols PW, and Preston-Martin S (2004). Alcohol consumption
and risk of adult-onset acute myeloid leukemia: results from a Los Angeles
County case-control study. Leuk Res 28(9), 927–931.
234 Alcohol and Hematological Malignancies Ji et al. Neoplasia Vol. 16, No. 3, 2014[29] Linet MS, Harlow SD, and McLaughlin JK (1987). A case–control study of
multiple myeloma in whites: chronic antigenic stimulation, occupation, and drug
use. Cancer Res 47(11), 2978–2981.
[30] Diaz LE, Montero A, Gonzalez-Gross M, Vallejo AI, Romeo J, and Marcos A
(2002). Influence of alcohol consumption on immunological status: a review. Eur
J Clin Nutr 56(Suppl 3), S50–S53.
[31] Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K,
Dörken B, Schmalz HG, Daniel PT, and Henze G (2001). Piceatannol, a
hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer
of apoptosis in the lymphoma cell line BJAB and in primary, leukemic
lymphoblasts. Leukemia 15(11), 1735–1742.
[32] Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, Kofler
R, Csordas A, and Greil R (2001). Resveratrol, a tumor-suppressive compound
from grapes, induces apoptosis via a novel mitochondrial pathway controlled by
Bcl-2. FASEB J 15(9), 1613–1615.[33] folkhälsoinstitut S. Alkoholstatistik 2006/Alcohol statistics 2006; 2008. http://
xn–folkhlsostmman-9hbf.se/PageFiles/3998/R200802_Alkoholstatistik06_
0802.pdf.
[34] International Agency for Research on Cancer. IARC Monogr Eval Carcinog
Risks Hum. Hepatitis Viruses. Vol 59: (Lyon: International Agency for Research
on Cancer); 1994.
[35] International Agency for Research on Cancer. IARC Monogr Eval Carcinog
Risks Hum. Biological agents. Vol 100B: (Lyon: International Agency for
Research on Cancer); 2011.
[36] Moorer WR (2003). Antiviral activity of alcohol for surface disinfection. Int J
Dent Hyg 1(3), 138–142.
[37] Luinstra K, Petrich A, Castriciano S, Ackerman M, Chong S, Carruthers S,
Ammons B, Mahony JB, and Smieja M (2011). Evaluation and clinical
validation of an alcohol-based transport medium for preservation and
inactivation of respiratory viruses. J Clin Microbiol 49(6), 2138–2142.
Neoplasia Vol. 16, No. 3, 2014 Alcohol and Hematological Malignancies Ji et al. 234.e1Supplementary MaterialTable W1. Risk of Cancers in the Esophagus and Upper Aerodigestive Tract among Individuals with AUDs.
Diseases Male Female All
O SIR 95% CI O SIR 95% CI O SIR 95% CI
Upper aerodigestive tract 1950 2.27 2.17 2.37 320 3.82 3.42 4.27 2270 2.41 2.31 2.51
Esophagus 641 2.12 1.96 2.29 94 4.10 3.31 5.02 735 2.26 2.10 2.43
O, observed number of cases; SIR, standardized incidence ratio; CI, confidence interval.
Bold type, 95% CI does not include 1.00.
